High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

23 October 2018

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

The OpACIN-Neo study, led by a team out of the Netherlands with a large number of patients recruited from Melanoma Institute Australia, showed a modified combination of the immunotherapies ipilimumab and nivolumab given prior to surgery produced a response in over 70% of patients. Importantly, there were drastically reduced side effects for patients and remarkably, none of these patients have relapsed to date.

Stage III patients are those whose melanoma has spread to their lymph nodes. Standard therapy for these patients is to undergo surgery to remove their melanoma, however those who undergo surgery alone have a significant risk (40-70%) of their disease recurring and progressing to Stage IV. Research in Stage IV melanoma patients demonstrates that combining ipilimumab and nivolumab is more effective than nivolumab alone, however this combination of drugs often causes extreme side effects for patients with many unable to continue treatment. Extrapolating from this data, the OpACIN-Neo study aimed to modify the dose of combined ipilimumab and nivolumab to reduce the incidence of toxicity while extending the efficacy seen in Stage IV patients to those with high-risk Stage III disease.

Previous research has shown that giving immunotherapy prior to surgery shrank the number of melanoma cells and increased long-term relapse-free survival. Neoadjuvant (pre-surgery) ipilimumab and nivolumab was also found to induce a stronger immune response, leading researchers to believe that when the immunotherapy is able to see the melanoma cells, they are able to assist the immune system to mount a more effective response.

In the OpACIN-Neo trial, researchers modified the standard dosing schedule by decreasing the dose of ipilimumab and increasing the dose of nivolumab and gave these prior to surgery. They found that after six weeks of therapy, the toxicity of the combination therapy was drastically reduced (only 20% of patients suffered a severe toxicity compared with those who received the standard dosing in that 6 weeks) while the efficacy was largely unchanged with a pathologic response seen in 77% of patients.

"These results are promising in that they provide an insight into the effects of altering the dosage and timing of giving combination immunotherapy to Stage III melanoma patients," said Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long. "To have such a high level of response, coupled with greatly reduced toxicity for patients, means we are heading in the right direction with this vital area of immunotherapy research. The high rate of pathological response is exciting, as we know from a pilot study that those patients who had a pathological response haven’t had disease recurrence."

Stage III melanoma patients with bulky lymph node disease have the worst prognosis of Stage III patients, with 70-80% of them expected to recur within the first two years. After three years of follow-up in this pilot study, every patient who presented with a pathological response is yet to recur.

Promising results from a host of clinical trials investigating the use of neoadjuvant therapies in metastatic melanoma are being analysed by the International Neoadjuvant Melanoma Consortium, which also met at ESMO. This international group of researchers and clinicians aims to increase collaboration and standardise efforts in neoadjuvant treatment for melanoma. "This is one of the most exciting things happening in drug therapy in melanoma and has the capacity to ultimately change clinical practice around the world," Professor Long added.

MIA joins Sydney Health Partners
22 Dec 2021

MIA joins Sydney Health Partners

Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.

Tags: melanoma
Congratulations Dr Hansol Lee
22 Dec 2021

Congratulations Dr Hansol Lee

Promising young MIA researcher conferred with University of Sydney PhD.

Tags: melanoma
Olympians join forces for melanoma warning
13 Dec 2021

Olympians join forces for melanoma warning

Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach

Tags: melanoma
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
07 Dec 2021

MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'

Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.

Tags: melanoma
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
06 Dec 2021

Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award

Honouring the exceptional impact of his work on communities around the world.

Tags: melanoma
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
03 Dec 2021

MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research

Awarded for their life-saving discoveries transforming melanoma patient care.

Tags: melanoma
Aussies urged to mark start of summer by checking their skin
01 Dec 2021

Aussies urged to mark start of summer by checking their skin

National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment

Tags: melanoma
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
24 Nov 2021

Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research

Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.

Tags: melanoma
AMC2021 conference wrap-up
23 Nov 2021

AMC2021 conference wrap-up

Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.

Tags: melanoma
Journalist and news reader Peter Overton our new National Ambassador
23 Nov 2021

Journalist and news reader Peter Overton our new National Ambassador

Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
19 Nov 2021

MIA researchers feature on prestigious Highly Cited Researchers 2021 List

MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.

Tags: melanoma
New research into importance of skin surveillance to save lives from melanoma
04 Nov 2021

New research into importance of skin surveillance to save lives from melanoma

New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.

Tags: melanoma
Game On Mole - saving lives this summer
31 Oct 2021

Game On Mole - saving lives this summer

With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever. 

Tags: melanoma
Melanoma March physical events in 2022
22 Oct 2021

Melanoma March physical events in 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022! 

Tags: melanoma
Community Fundraising Wrap Up July-Sept 2021
15 Oct 2021

Community Fundraising Wrap Up July-Sept 2021

Read more about the wonderful MIA community fundraising initiatives held recently.

Tags: melanoma
Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Melanoma Bike Bash 2021: What a ride!
20 Sep 2021

Melanoma Bike Bash 2021: What a ride!

Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
MIA researchers awarded $7.2m in NHMRC grants for health research
15 Sep 2021

MIA researchers awarded $7.2m in NHMRC grants for health research

Three MIA researchers at University of Sydney received grants to further their important melanoma research.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.